244 related articles for article (PubMed ID: 10969855)
1. Maternal serum triple analyte screening in pregnancy.
Cate S
Am Fam Physician; 2000 Aug; 62(4):738, 740. PubMed ID: 10969855
[No Abstract] [Full Text] [Related]
2. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
[TBL] [Abstract][Full Text] [Related]
3. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
Kristoffersson U; Nørgaard-Pedersen B
Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
[No Abstract] [Full Text] [Related]
4. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
Biggio JR; Morris TC; Owen J; Stringer JS
Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
[TBL] [Abstract][Full Text] [Related]
5. Rapid aneuploidy test for positive Down screening: who is willing to pay for it?
Lo TK; Leung WC; Lau WL; Lam H; Lai FK; Ng LS; Wong WC; Chan A; Chin RK
J Matern Fetal Neonatal Med; 2010 Jul; 23(7):747-9. PubMed ID: 19701862
[No Abstract] [Full Text] [Related]
6. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA
Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588
[TBL] [Abstract][Full Text] [Related]
7. Down syndrome: prenatal risk assessment and diagnosis.
Newberger DS
Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
[TBL] [Abstract][Full Text] [Related]
8. Sequential pathways of testing after first-trimester screening for trisomy 21.
Malone FD
Obstet Gynecol; 2005 Feb; 105(2):438; author reply 438-9. PubMed ID: 15684179
[No Abstract] [Full Text] [Related]
9. Current methods of prenatal screening for Down syndrome and other fetal abnormalities.
Saller DN; Canick JA
Clin Obstet Gynecol; 2008 Mar; 51(1):24-36. PubMed ID: 18303497
[TBL] [Abstract][Full Text] [Related]
10. First- and second-trimester evaluation of risk for Down syndrome.
Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
[TBL] [Abstract][Full Text] [Related]
11. Low MSAFP and new biochemical markers for Down syndrome: implications for genetic counselors.
Kloza EM
Birth Defects Orig Artic Ser; 1990; 26(3):31-43. PubMed ID: 1709365
[No Abstract] [Full Text] [Related]
12. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
Benn PA; Ying J; Beazoglou T; Egan JF
Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
[TBL] [Abstract][Full Text] [Related]
13. Maternal serum screening.
Lofsky S
CMAJ; 1999 Apr; 160(8):1125-6. PubMed ID: 10234332
[No Abstract] [Full Text] [Related]
14. Integrated, sequential, and contingent screening for Down syndrome - local needs should drive methodology.
Wyatt P
Prenat Diagn; 2007 Feb; 27(2):186-7. PubMed ID: 17266162
[No Abstract] [Full Text] [Related]
15. The evolving prenatal screening scene.
Reddy UM
Obstet Gynecol; 2007 Jul; 110(1):2-4. PubMed ID: 17601887
[No Abstract] [Full Text] [Related]
16. Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005.
Muller PR; Cocciolone R; Haan EA; Wilkinson C; Scott H; Sage L; Bird R; Hutchinson R; Chan A
Am J Obstet Gynecol; 2007 Apr; 196(4):315.e1-7; discussion 285-6. PubMed ID: 17403402
[TBL] [Abstract][Full Text] [Related]
17. Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers.
Hackshaw AK; Wald NJ
Prenat Diagn; 2001 Jan; 21(1):58-61. PubMed ID: 11180243
[TBL] [Abstract][Full Text] [Related]
18. On the current dilemma of Down syndrome screening.
Rose NC
Obstet Gynecol; 2006 Jan; 107(1):2-3. PubMed ID: 16394031
[No Abstract] [Full Text] [Related]
19. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
Ohno M; Caughey A
Prenat Diagn; 2013 Jul; 33(7):630-5. PubMed ID: 23674316
[TBL] [Abstract][Full Text] [Related]
20. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis.
Cuckle H; Benn P; Pergament E
Prenat Diagn; 2013 Jul; 33(7):636-42. PubMed ID: 23674341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
